The ability of different cell types t o cooperate in the metabolism of reactive intermediates of arachidonic acid such as leukotriene A, (LTA,) is currently receiving considerable attention. Of critical importance is the demonstration that transfer of LTA, could occur under conditions when relatively low amounts of LTA, are produced such as would be expected for in vitro receptor-mediated stimulation. Stimulation of human neutrophils with a combination of chemotactic factor (formyl-methionyl-leucyl-phenylalanine, FMLP) and phagocytosable particles (opsonized zymosan) resulted in little production of LTC, alone, but measurable quantities appeared when platelets were coincubated. When these agonists were added t o platelets alone in the absence of neutrophils, no LTC, was produced. In the presence of stimulated neutrophils, the final synthesis of LTC, was shown t o occur within the platelets (from neutrophil-derived LTA,) by experiments using platelets that had been prelabeled with 36S-cysteine t o label intracellular platelet glutathione. Other 36S-labeled sulfidopeptide leukotriene metabolites were also produced in this coincubation of neutrophils and platelets. The observed synergy between FMLP and opsonized zymosan in the production of ECENTLY, cooperation between cells in the processing R of reactive precursors and intermediates of arachidonic acid metabolism into biologically active compounds has emerged as an important concept. It is believed that such cell-cell interactions could significantly alter the profile of eicosanoid synthesis. This belief is based on an earlier suggestion' followed by biochemical demonstration that platelet-derived prostaglandin endoperoxide H, could be metabolized by vascular endothelial cells into the potent platelet inhibitor and vasodilator prostacyclin (PGI,)., Later, transcellular processes were also described for the 5-lipoxygenase pathway of arachidonate metab~lism.~.~ In this pathway, the allylic epoxide product leukotriene A, (LTA,),3 can be metabolized into LTC, and LTB, depending on the specific cell type. Thus, blood or vascular cells, themselves devoid of 5-lipoxygenase activity, could nevertheless partici- These previous investigations of the transcellular metabolism of neutrophil-derived LTA, were made using the calcium ionophore A23187 as a stimulatory agent to generate maximal amounts of LTA,, however. Thus, we wished to determine whether LTA, transfer would occur when synthesis was orders of magnitude less. Such situations would exist if moderate, but physiologically relevant, activators of neutrophils were used as a model for in vivo activation. In addition, because neutrophils are known to interact in complicated and intricate ways with both platelets and endothelial cells in pathologic situations, we believed it necessary to determine whether activation of platelets or endothelial cells could alter LTA, metabolism. Furthermore, we determined whether previous exposure of platelets to various quantities of exogenously provided LTA, would affect production of thromboxane A, (TXA,) induced by thrombin.
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pate in formation of leukotrienes; eg, human erythrocytes were shown to convert LTA, to LTB,.5 Porcine aortic endothelial cells have also been shown to transform the LTA, synthesized by leukocytes into LTC; and human umbilical vein endothelial cells (HUVEC) have been reported to generate LTB,, LTC,, LTD,, and LTE, from LTA,.' Recently, we documented that human platelets are able to transform LTA, produced by neutrophils stimulated with the calcium ionophore into LTC,. 6 These previous investigations of the transcellular metabolism of neutrophil-derived LTA, were made using the calcium ionophore A23187 as a stimulatory agent to generate maximal amounts of LTA,, however. Thus, we wished to determine whether LTA, transfer would occur when synthesis was orders of magnitude less. Such situations would exist if moderate, but physiologically relevant, activators of neutrophils were used as a model for in vivo activation. In addition, because neutrophils are known to interact in complicated and intricate ways with both platelets and endothelial cells in pathologic situations, we believed it necessary to determine whether activation of platelets or endothelial cells could alter LTA, metabolism. Furthermore, we determined whether previous exposure of platelets to various quantities of exogenously provided LTA, would affect production of thromboxane A, (TXA,) induced by thrombin.
MATERIALS AND METHODS
Synthetic LTA,, methyl ester, a gift of Dr F. A. Fitzpatrick (Upjohn, Kalamazoo, MI), was hydrolyzed according to a published procedure to yield the sodium salt of the free acid." 'H-LTC, (1 38 Ci/mmol) was obtained from New England Nuclear (Boston, MA). LTC,, LTD,, and LTE,, were a gift of Dr J Rokach (Merck Frosst, Montreal, Canada). The rabbit anti-LTC, was a gift from Dr E. Hayes (Merck, Sharpe and Dohme, Rahway, NJ). The rabbit anti-LTE, was a gift from Dr Philippe Pradelles (CEA,
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Blood, MO) . Zymosan (ICN, Cleveland, OH) was prepared as described" and was boiled for 30 minutes before opsonization. Serum-opsonized zymosan was prepared from a pool of frozen human serum (stored at -7OOC) by incubating particles (2 mg/mL) for 1 hour at 37OC. The opsonized zymosan was washed in saline and kept in Hank's balanced salt solution (HBSS) containing 40 mmol/L EDTA at 0°C until use (within <2 weeks after preparation). Prostaglandin E, (PGE,) was purchased from Cayman Chemical (Ann Arbor, MI). High-performance liquid chromatography (HPLC)-grade solvents were obtained from Fisher Scientific (Springfield, NJ). Apex I1 octadecyl reversed-phase HPLC cartridges (5 pm, Jones Chromatography, Mid Glamorgan, England) were used for quantitation and characterization of leukotrienes after being washed with EDTA.', Human venous blood (6 vol) was obtained from adult human volunteers who had not received medication for at least 1 week. Blood was anticoagulated with acid-citrate-dextrose anticoagulant (ACD, National Institutes of Health formula A) (1 vol) and centrifuged for 15 minutes at 120 g a t room temperature. The platelet-rich plasma (PRP) was transferred to a polypropylene tube with a plastic pipette and was then further acidified to pH 6.5 by addition of 1/10 vol ACD-A and centrifuged for 15 minutes at 400 g. The platelets were washed using the method of Preparation of human polymorphonuclear leukocytes. Suspensions containing neutrophils (>98% viable) were prepared using a plasma Percoll gradient by techniques that minimize exposure to bacterial endotoxin as previously de~cribed.'~ The contamination of these cells by nonadhering platelets or RBCs was less than 3% and 5%, respectively, as estimated by phase-contrast microscopy. The cells were resuspended in HBSS/BSA to cell concentrations indicated in the legends to Figs 1 through 3. Experiments were performed to examine the production of thromboxane B, (TXB,) by neutrophil and neutrophil/platelet mixtures stimulated maximally with A23187. Neutrophils alone produced 2.1 * 0.8 ng TXB,/S x lo6 neutrophils when stimulated with 1 rmol/L ionophore (n = 4). In the presence of 2 x 10' platelets, 1,509 f 240 ng TXB,/106 neutrophils was produced. From these figures, we can estimate that it would require a contamination of only one platelet per 20 neutrophils to achieve the levels of TXB, observed with neutrophil preparations. This degree of platelet contamination is typical.
HUVEC were harvested from umbilical veins," cultured in MCDB 13116 supplemented with 5% fetal bovine serum (FBS), 10 ng/mL epidermal growth factor (Collaborative Research, Bedford, MA) 1 pg/mL hydrocortisone (Sigma) and 100 U/mL penicillin with 100 U/mL streptomycin (GIBCO, Grand Island, NY). Primary cultures were grown to confluence and subcultured at a split ratio of 1:2 into assay wells. Both cobblestone morphology and the presence of factor VIII-related antigen, measured by indirect immunofluorescence using goat anti-human factor VI11 immunoglobulin (Atlantic Laboratories, Scarborough, MA) were used to identify the cells. They were plated in 35-mm wells (Costar, Cambridge, MA) and maintained in a 37OC, 5% CO, humidified atmosphere.
Transcellular metabolism of neutrophil-derived LTA,. Combinations of platelets (0.35 x lo9) and neutrophils (7 x lo6) and 1 mL HBSS, pH 7.4, containing 1 g/L BSA (final volume) were allowed to equilibrate for 5 minutes at 37OC. Incubations were initiated by addition of opsonized zymosan (30 to 35 particles per neutrophil) and/or FMLP at concentrations from lo-* to mol/L. All incubations were performed at 37OC for 30 minutes. The reaction was stopped by addition of 1 vol ice-cold methanol to each tube, which was then allowed to stand for 1 hour at -2OOC. The cells and any precipitated material were removed by centrifugation at 12,OOOg for 2 minutes. Incubations were performed in duplicate with three different donors. The supernatants were dried under vacuum after previous addition of 20,000 dpm of 'H-LTC,. The dried extract was suspended in 1 mL 0.1 mol/L phosphate buffer (pH 7.4) containing 1 g/L BSA. To these tubes was added 0.1 U each of y-glutamyl transpeptidase and leucine aminopeptidase, and the system was incubated overnight at room temperature to convert peptido leukotrienes into LTEql' Addition of 'H-LTC, permitted evaluation of losses during sample handling at various stages. Furthermore, analysis of representative samples by HPLC enabled verification that enzymatic transformation of LTC, and LTD, to LTE, was complete.
Platelets were prepared according to the procedures described above. After washing, they were suspended at 0.2 x lo9 cells/mL in HBSS, pH 7.4, containing no BSA. 
Cell incubation with LTA,.
E
Exogenous LTA, was then added at different concentrations to the platelet suspensions (0.5 mL) for 10 minutes at 37OC. Thrombin (0.1 U/mL) was then added, and platelets were incubated for 3 minutes more. The cells were transferred to tubes containing ice-cold 0.1 mol/L EDTA and centrifuged for 1 minute at 12,000 g. The supernatant was then analyzed for TXB, content using a previously described enzyme immunoassay (EIA).'* Two separate experiments were performed on platelets obtained from two different donors. In other experiments, platelets or endothelial cells in 35-mm wells were allowed to equilibrate for 5 minutes at 37OC in 1 mL HBSS/BSA and then incubated with various amounts of thrombin (0.01 to 10 U/mL). After this stimulation, the cells were incubated at 37"C for 30 minutes with LTA, at the concentrations described in legends to Figs 1 through 3 . At the end of this incubation, 1 mL ice-cold methanol was added to the cells and the tubes were kept frozen for analysis by HPLC or by EIA for LTC, (described below). In Figs 1  through 3 , the values represent the average of three to five different experiments.
RP-HPLC was performed using a Beckman gradient HPLC system and an ultraviolet (UV) detector (Spectromonitor 111, LDC, Riviera Beach, FL). A linear gradient was used starting with 100% solvent A (methanol/water/phosphoric acid, 30:70:0.02, buffered to pH 5.7 with ammonium hydroxide) and proceeding to 100% methanol in 30 minutes with a flow rate of 1 mL/min. The identity of the peaks was assessed by coelution with authentic standards, UV spectroscopy, immunoreactivity and, when appropriate, radioactivity content was followed by continuous radioactive monitoring using an on-line HPLC scintillation detector (Flo-one, Radiomatic, Tampa, FL). In some elutions, the UVabsorbing radioactive peaks were analyzed by EIA.
Quantitative determination of sulfidopeptide leukotrienes. Quantitation of LTC, by HPLC was made using PGB, as an internal standard as described previ~usly.'~ A sensitive EIA technique with acetyl cholinesterase coupled to LTC, as the enzymatic tracer was also used (a gift from Dr P. Pradelles, CEA, Saclay, France). The EIA protocol used a double-antibody technique with 96-well microtiter plates coated with a anti-rabbit IgG monoclonal antibody (MoAb) (a gift from Dr Pradelles) and was performed as described previ0us1y.l~ The quantitation of LTE, was made with a newly developed EIA for LTE, which essentially follows that previously described for other eicosanoids." Statistical analyses were made with Student's unpaired t test. 
RESULTS
Transcellular metabolism of neutrophil-derived LTA, by platelets. Previous work has suggested that LTA, from neutrophils can be metabolized within the platelet to yield sulfidopeptide leukotrienes. To test the hypothesis that production of LTC, resulted from platelet conversion of neutrophil-derived LTA, after physiologic stimulation, "S-cysteinelabeled platelets were used in neutrophil coincubations. Exposure of platelets to radiolabeled cysteine resulted in production of intracellular 'SS-glutathione,20 which was then available as a substrate for LTC, synthetase within the platelet. Formation of 35S-labeled LTC, as a final product (Fig l) , would therefore indicate that the LTA, had been converted within the platelet. Because the amount of LTC, generated in these types of experiments was at the UV detection limit for leukotrienes by HPLC analysis, separated HPLC fractions were analyzed by EIA and radioactivity was analyzed using an on-line HPLC scintillation detector. To minimize any transfer of "S-cysteine or 3SS-glutathione from the labeled platelets during coincubation with the neutrophils, 50 pmol/L cysteine (unlabeled) was added to the incubation medium in these experiments?' In separate experiments, we verified that addition of cysteine (50 pmol/L) did not affect the quantitative production of LTC,.
When the neutrophils alone were stimulated with opsonized zymosan and FMLP mol/L), almost no immunoreactive material could be detected (described below). When platelets were added, however, the "S radioactivity profile, as well as analysis of the HPLC fractions by EIA, indicated radioactive and immunoreactive peaks corresponding to the elution of LTC, had appeared (Fig 1) . These results were consistent with our previous data of transcellular metabolism of LTA, by neutrophils and platelets when the calcium ionophore A23187 was used as the s t i m u h 6 In some other experiments, we also found immunoreactive LTD, and E,, probably caused by further metabolism of LTC, into those compounds.
Owing to the potential presence of multiple metabolites of the sulfidopeptide leukotrienes, subsequent experiments involving quantitative measurements of sulfidopeptide leukotrienes were assessed after conversion of LTC, and LTD, into LTE, by addition of y-glutamyl transpeptidase and leucine aminopeptidase to the postincubation supernatants. This is known to metabolize LTC, to LTE, effi~ient1y.l~ In representative experiments, the extent of metabolism was monitored by HPLC and scintillation counting to assess conversion of 'H-LTC, added as an internal standard. More than 80% conversion was always observed.
As shown in Fig 2, stimulation of human neutrophils with FMLP mol/L) or opsonized zymosan (25 to 40 particles per cell) alone did not result in formation of significant amounts of sulfidopeptide leukotrienes (as measured by LTE, equivalents) although the levels obtained from opsonized zymosan stimulation were higher than those obtained from unstimulated cells (0.1 14 f 0.035 pmol/106 neutrophils as compared with 0.054 0.002 for the control, mean SEM, n = 6). Such data are in good agreement with previous reports demonstrating that, in contrast to eosinophils, neutrophils alone have only a small capacity to synthesize LTC,." Addition of platelets to the suspension resulted in little alteration in sulfidopeptide leukotriene biosynthesis induced by FMLP alone (0.042 + .005 pmol/ lo6 neutrophils LTE, equivalents), but a slight increase in these products was observed when neutrophil/platelet suspensions were stimulated with opsonized zymosan (0.182 f .037 pmol/ lo6 neutrophils LTE,). The combination of FMLP (lo-" mol/L) and opsonized zymosan added to a mixed suspension of neutrophils and platelets resulted in a substantial increase in sulfidopeptide leukotriene biosynthesis, however (0.70 & .20 pmol/106 neutrophils), as compared with neutrophils stimulated in the absence of platelets (0.18 f 0.03 pmol/ 1 O6 neutrophils). Furthermore, a dose-dependent increase occurred in production of sulfidopeptide leukotrienes from to mol/L FMLP when opsonized zymosan and platelets were present in the incubation system. Indeed, even at lo-' mol/L FMLP (with opsonized zymosan and platelets) there appeared to be greater than threefold enhancement in production of sulfidopeptide leukotrienes as compared with that obtained without FMLP present.
Influence of recipient cell activation on metabolism of LTA, into LTC,. The experiments so far described resulted in data that could not rule out the additional possibility that metabolism of LTA, generated from neutrophils also required activation of endothelial cells or platelets, even though the glutathione-S-transferases are not believed to require activation.22 Accordingly, the capacity of platelets and endothelial cells (as recipient cells) to metabolize exogenous LTA, into LTC, was examined in the presence of increasing concentrations of thrombin, which is known to activate both platelets and endothelial cells, but not neutrophil^?^ Addition of thrombin to platelets induced their activation, as reflected by a dose-related production of TXB,. Addition of a constant amount of LTA, 10 minutes after thrombin stimulation, however, was accompanied by LTC, production independent of the presence of thrombin (Fig 3A) . Similar results were obtained with endothelial cells, in which 6-keto-PGF,, production was dependent on the concentration of thrombin, whereas LTC, production was not affected (Fig 3B) .
In the control experiments, production of LTC, from endothelial cells after addition of LTA, was evaluated by immunoreactivity and HPLC chromatography. A major peak of immunoreactivity eluting from the HPLC at the time expected for LTC, was evaluated by UV spectroscopy. In experiments using 5 pmol/L LTA, incubated with endothelial cells, quantitation of LTC, production measured by EIA was 210 pmol/mL and LTC, production measured by HPLC techniques was 230 pmol/mL. The EIA technique could detect 0.2 pmol/mL LTC,, but the HPLC techniques were sensitive only for quantities greater than 20 pmol/mL. By the HPLC techniques, however, there was no evidence for LTD, or LTE,. Although the production of LTC, by endothelial cells was in good agreement with results of a previous r e p~r t ,~ we could find no evidence for the occurrence of LTB,, LTD,, or LTE, as reported by other investigators." Additional experiments were performed with endothelial cells The influence of LTA, concentration on formation of TXAl after thrombin activation was also evaluated. In these experiments, platelets were preincubated with LTA, a t different concentrations for 10 minutes at 37OC. Thrombin was then added to platelets for another 3-min incubation period. Analysis of the supernatant (Table 1) indicated that LTC, production was linearly related to the concentration of LTA, added to the platelet incubations, as expected from previous experiments. Furthermore, thrombin-induced formation of TXA, (as measured by TXB,) was not affected by previous exposure of the platelet to LTA,. Only a t the highest concentrations of LTA, (10 pmol/L) did there appear to be a decrease in thromboxane production.
DISCUSSION
The finding that both endothelial cells and platelets have the capacity to metabolize LTA, into LTC, is of potential interest in relationship to the interaction of the vessel wall with blood cells under pathologic circumstances as well as in the pharmacologic effects of the peptidoleukotrienes on vessel tone and the alteration of vascular permeability. In our previous report, we showed that platelets efficiently metabolized LTA, generated from neutrophils by action of the calcium ionophore A23 1 87.6 This nonphysiologic stimulus had previously been used to demonstrate transcellular cooperation in production of LTB, or LTC, by neutrophilerythrocyte' and neutrophil-endothelial cell interaction^.^.'
The concentrations of leukotrienes achieved using the calcium ionophore were difficult to reconcile with the low production of arachidonate products obtained using receptorspecific inducer of neutrophil activation, however. In the present study, we showed that use of multiple stimuli can significantly enhance production of arachidonate products to levels close to that achieved with the calcium ionophore.
Direct evidence for transcellular metabolism of LTA, from neutrophils to platelets following a more relevant stimulus was illustrated by studies with platelets prelabeled with 35S-cysteine (Fig 1) . Platelets possess a substantial concentration of endogenous glutathione that can be labeled by ''S-cy~teine,~~ and the observation of "S-labeled LTC, resulting from these experiments could therefore be attributed to conversion of neutrophil-derived LTA, into LTC, using the glutathione in the platelets.6 Identification of transcellular-derived LTC, was made by HPLC coelution of "S-radiolabeled with a 280-nm absorbing component a t the LTC, retention time as well as immunoreactivity for LTC, by an EIA at the same retention time. Reutilization of "S-cysteine was prevented by addition of excess unlabeled cysteine in the reaction mixture. Metabolism of LTA, in the medium by glutathione transferase (and glutathione) released from lysed platelets was not believed to be a factor because the glutathione concentrations would have been too low (even if all the platelets had lysed). Finally, uptake of labeled glutathione into the neutrophils was rendered unlikely because of the concentration issue described above and because this molecule does not readily penetrate cell membranes.
The subsequent metabolism and degradation of LTC, by activated neutrophils, which might have reduced the estimate of sulfidopeptide leukotrienes produced (Fig l ) , has already been reported by other investigator^.^'*^' Although platelets were used throughout this study as a model for cellular interactions with neutrophils, endothelial cells appeared to share with platelets some common features of transcellular metabolism of LTA, into LTC,.
In the present study, opsonized zymosan and FMLP alone initiated production of only low levels of leukotrienes in the presence of recipient cells such as platelets. The dose of FMLP used was sufficient to elicit an oxygen burst in the neutrophil,26 and in parallel experiments consistently does so. The results are in keeping with the low levels of eicosanoids that are generally produced by neutrophils stimulated in this fashion.27 Accordingly, a combination of the two stimuli was used. In part, the rationale for this approach derived from our previous work on the synergism of different stimuli in their interaction with neutrophils-the "priming" phenomenon. 26 Seeger et a12* reported the combined effect of C5a and complement component C8 on LTB, generation by human neutrophils. In addition, we wished to examine the effects of these two commonly used activating agents because of the likely occurrence of mixed stimuli in vivo, especially mixes of chemotactic agents and phagocytosable particles. With these two stimuli, an increase of LTC, biosynthesis was achieved when platelets were included in the incubation mixture with the neutrophils. This observation further supports a possible occurrence of such transcellular events in vivo. Although the amount of LTC, obtained with opsonized zymosan and FMLP (-0.5 to 1 pmol/106 neutrophils) was much lower than that achieved with the calcium ionophore (nearly 100 pmol/106 neutrophils from A23187), these nanomolar concentrations are nonetheless compatible with significant biological activity." For example, the sulfidopeptide leukotrienes LTC, at mol/L has been reported to reduce coronary blood flow significantly in isolated guinea pig heart.30 Our results indicate (Fig 2) that four to six times this concentration is produced in these in vitro incubations.
That conversion of LTA, into LTC, was unaffected by the degree of activation of the recipient platelets or endothelial cells is in good agreement with what is known of other For personal use only. on September 14, 2017. by guest www.bloodjournal.org From glutathione transferases." The description of a platelet function perhaps described as parallel to activation is also worth emphasis because most other capacities of these cells are closely related to their reactivity to stimuli. It also indicates that aggregated platelets (including those concentrated locally in a thrombus) are likely to retain their capacity to metabolize LTA,, which could be released by a nearby neutrophil. Furthermore, we showed that transcellular production of LTC, can occur with aspirin-treated platelets. Transcellular biosynthesis of vasoconstrictor LTC, from neutrophil LTA, can thus occur within platelets that can no longer synthesize thromboxane owing to cyclooxygenase inhibition, but such platelets still retain capacity to produce a vasoconstrictor.
The interactions of neutrophils with endothelial cells and/or platelets may represent an important source of LTC, production in the systemic circulation. Thus, LTC, production by the latter cells may be as quantitatively important as that which is elicited from eosinophils, mast cells, or mononuclear phagocyte^.^' Neutrophils, platelets, and endothelial cells clearly interact with each other in vivo. The reality of the proposed transcellular biosynthetic events under such pathophysiologic circumstances has not been clearly demonstrated, however. Likely possibilities may include aspirininduced asthma, in which platelets are believed to be myocardial infar~tion:~ or events associated with inflammatory reactions, in which platelets have been suggested to contribute as helper cells to neutrophil-dependent reaction^.^,
